

## Appendix F. Aim 2 Single Augmenting Class Analyses

## Appendix F: Aim 2 Single Augmenting Class Analyses

### Tables - Change in Outcomes

#### Unweighted Changed in Weight

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	206.29	208.41	2.1206	(1.9983,2.2428)	<.0001	1.02798
<b>Quetiapine</b>	206.11	208.07	1.9626	(1.8154,2.1097)	<.0001	0.95222
<b>Risperidone</b>	208.77	210.98	2.2144	(1.98,2.4488)	<.0001	1.06069
<b>Olanzapine</b>	195.41	199.08	3.6717	(3.0747,4.2688)	<.0001	1.87901
<b>Mirtazapine</b>	200.99	203.97	2.9822	(2.8478,3.1166)	<.0001	1.48377
<b>Prazosin</b>	214.61	216.08	1.4719	(1.3855,1.5584)	<.0001	0.68588
<b>Tricyclics</b>	211.08	213.15	2.0753	(1.8812,2.2693)	<.0001	0.98317
<b>Amitriptyline</b>	211.14	213.28	2.1433	(1.9444,2.3421)	<.0001	1.01508
<b>Imipramine</b>	209.76	210.46	0.6973	(-0.1823,1.577)	0.12	0.33245

#### Propensity Score Weighted Changes in Weight

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	206.97	209.08	2.1051	(1.9836,2.2266)	<.0001	1.01709
<b>Quetiapine</b>	206.62	208.56	1.9417	(1.7953,2.088)	<.0001	0.93972
<b>Risperidone</b>	209.74	211.97	2.2247	(1.9915,2.4579)	<.0001	1.06067
<b>Olanzapine</b>	196.32	199.95	3.6267	(3.034,4.2195)	<.0001	1.84732
<b>Mirtazapine</b>	201.8	204.99	3.198	(3.0646,3.3314)	<.0001	1.58479
<b>Prazosin</b>	214.35	215.7	1.3495	(1.2623,1.4367)	<.0001	0.6296
<b>Tricyclics</b>	210.91	212.97	2.066	(1.8761,2.2559)	<.0001	0.97959
<b>Amitriptyline</b>	211.01	213.13	2.1198	(1.9252,2.3144)	<.0001	1.00457
<b>Imipramine</b>	208.85	209.91	1.0645	(0.1957,1.9334)	0.0164	0.50973

#### Number of Windows for Weight

Medication Group	n(pre)	n(post)
<b>Antipsychotics</b>	30292	29949
<b>Quetiapine</b>	20373	20155
<b>Risperidone</b>	8343	8252
<b>Olanzapine</b>	1576	1542
<b>Mirtazapine</b>	23833	23453
<b>Prazosin</b>	49458	48369
<b>Tricyclics</b>	10385	10226
<b>Amitriptyline</b>	9906	9745
<b>Imipramine</b>	479	481

#### Number of Weight Measurements per Person

	Pre-Index Year	Post-Index Year
	Median (IQR)	Median (IQR)
<b>Antipsychotics</b>	4(2,6)	4(2,7)
<b>Mirtazapine</b>	4(2,6)	4(2,7)
<b>Prazosin</b>	3(2,6)	4(2,6)
<b>Tricyclics</b>	5(3,7)	5(3,8)

### Unweighted Changes in A1c

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
Antipsychotics	6.2054	6.2339	0.02841	(0.0132,0.0436)	0.0002	0.45789
Quetiapine	6.1791	6.2059	0.02686	(0.0086,0.0451)	0.004	0.43471
Risperidone	6.2937	6.3153	0.02155	(-0.0075,0.0506)	0.1455	0.34248
Olanzapine	6.0545	6.1448	0.09029	(0.0163,0.1643)	0.0169	1.49134
Mirtazapine	6.2708	6.4141	0.1433	(0.1256,0.1609)	<.0001	2.28484
Prazosin	6.2627	6.2745	0.01177	(0.0007,0.0229)	0.0379	0.18787
Tricyclics	6.4542	6.5347	0.08051	(0.0535,0.1075)	<.0001	1.24741
Amitriptyline	6.4571	6.5398	0.08264	(0.0548,0.1105)	<.0001	1.27986
Imipramine	6.3919	6.4273	0.03543	(-0.0657,0.1365)	0.4904	0.55422

### Propensity Score Weighted Changes in A1c

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
Antipsychotics	6.2083	6.2395	0.03118	(0.0163,0.0461)	<.0001	0.50223
Quetiapine	6.1778	6.2073	0.02952	(0.0116,0.0475)	0.0013	0.47792
Risperidone	6.3031	6.3253	0.02224	(-0.0063,0.0508)	0.127	0.35281
Olanzapine	6.0616	6.1712	0.1097	(0.0364,0.183)	0.0034	1.80961
Mirtazapine	6.2218	6.3674	0.1457	(0.1281,0.1632)	<.0001	2.34139
Prazosin	6.3206	6.3284	0.007772	(-0.0037,0.0192)	0.1837	0.12296
Tricyclics	6.3147	6.412	0.09731	(0.0718,0.1228)	<.0001	1.54101
Amitriptyline	6.3172	6.4173	0.1001	(0.0738,0.1264)	<.0001	1.5849
Imipramine	6.2666	6.312	0.04538	(-0.0491,0.1399)	0.3449	0.72422

### Number of Windows for A1c

Medication Group	n(pre)	n(post)
Antipsychotics	15408	17589
Quetiapine	10239	11670
Risperidone	4416	5058
Olanzapine	753	861
Mirtazapine	12659	12806
Prazosin	26985	27060
Tricyclics	5797	5837
Amitriptyline	5535	5568
Imipramine	262	269

### Unweighted Changes in Glucose

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
Antipsychotics	112.35	113.93	1.5715	(1.1039,2.0391)	<.0001	1.39869
Quetiapine	111.65	112.94	1.2855	(0.7333,1.8376)	<.0001	1.1513
Risperidone	114.67	116.51	1.8411	(0.8633,2.8189)	0.0002	1.60551
Olanzapine	109.11	112.75	3.6351	(1.9559,5.3143)	<.0001	3.33146
Mirtazapine	113.27	116.95	3.6777	(3.1609,4.1944)	<.0001	3.24685
Prazosin	112.51	114.24	1.7326	(1.3776,2.0875)	<.0001	1.53994
Tricyclics	116.78	119.36	2.5837	(1.7361,3.4312)	<.0001	2.21245
Amitriptyline	116.78	119.46	2.6797	(1.8047,3.5547)	<.0001	2.29472
Imipramine	116.8	117.55	0.7438	(-2.5223,4.0098)	0.6546	0.63677

### Propensity Score Weighted Changes in Glucose

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
Antipsychotics	112.36	114.01	1.6457	(1.1779,2.1136)	<.0001	1.4647
Quetiapine	111.57	112.91	1.3406	(0.7874,1.8939)	<.0001	1.20158
Risperidone	114.84	116.72	1.8775	(0.9042,2.8508)	0.0002	1.63483
Olanzapine	109.12	113.32	4.2074	(2.5122,5.9026)	<.0001	3.85585
Mirtazapine	111.65	115.3	3.647	(3.1469,4.1471)	<.0001	3.26638
Prazosin	114.09	115.72	1.6252	(1.2578,1.9926)	<.0001	1.42448
Tricyclics	113.44	115.87	2.4338	(1.6329,3.2347)	<.0001	2.14546
Amitriptyline	113.4	115.87	2.4663	(1.6397,3.2928)	<.0001	2.17483
Imipramine	114.2	116.08	1.8812	(-1.2945,5.057)	0.2449	1.6473

### Number of Windows for Glucose

Medication Group	n(pre)	n(post)
Antipsychotics	27511	27209
Quetiapine	18454	18180
Risperidone	7607	7605
Olanzapine	1450	1424
Mirtazapine	21956	21197
Prazosin	44292	42565
Tricyclics	9548	9279
Amitriptyline	9102	8831
Imipramine	446	448

### Unweighted Changes in Triglycerides

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
Antipsychotics	169.03	176.95	7.9252	(6.4212,9.4292)	<.0001	4.68873
Quetiapine	168.62	178.15	9.5219	(7.6391,11.4047)	<.0001	5.64687
Risperidone	171.33	174.11	2.7805	(0.1009,5.46)	0.042	1.62285
Olanzapine	161.99	177.04	15.0536	(8.5294,21.5778)	<.0001	9.29289
Mirtazapine	163.62	177.86	14.2401	(12.5127,15.9675)	<.0001	8.70304
Prazosin	171.49	171.63	0.1463	(-0.9905,1.2831)	0.8008	0.08532
Tricyclics	179.1	183.7	4.595	(2.0849,7.1051)	0.0003	2.56556
Amitriptyline	179.74	184.5	4.7673	(2.1654,7.3691)	0.0003	2.65235
Imipramine	165.99	167.58	1.5915	(-6.8555,10.0385)	0.7112	0.95882

### Propensity Score Weighted Changes in Triglycerides

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
Antipsychotics	169.12	176.73	7.6104	(6.1394,9.0813)	<.0001	4.50003
Quetiapine	168.53	177.91	9.3773	(7.5337,11.2209)	<.0001	5.56417
Risperidone	171.81	173.91	2.0998	(-0.5037,4.7033)	0.1139	1.22214
Olanzapine	161.92	177.2	15.2784	(8.7712,21.7856)	<.0001	9.43567
Mirtazapine	164.71	179.21	14.497	(12.7616,16.2325)	<.0001	8.80158
Prazosin	172.12	171.68	-0.4412	(-1.5788,0.6964)	0.4472	-0.25631
Tricyclics	177.48	182.34	4.8598	(2.427,7.2925)	<.0001	2.73824
Amitriptyline	178.24	183.36	5.1166	(2.5967,7.6366)	<.0001	2.87064
Imipramine	162.87	163.4	0.529	(-8.0876,9.1456)	0.904	0.32479

### Number of Windows for Triglycerides

Medication Group	n(pre)	n(post)
Antipsychotics	25251	25247
Quetiapine	16903	16887
Risperidone	7022	7079
Olanzapine	1326	1281
Mirtazapine	20294	19296
Prazosin	40967	38912
Tricyclics	8749	8382
Amitriptyline	8351	7974
Imipramine	398	408

### Unweighted Changes in HDL Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	43.8533	43.3981	-0.4553	(-0.574,-0.3365)	<.0001	-1.03814
<b>Quetiapine</b>	44.0337	43.464	-0.5697	(-0.7171,-0.4223)	<.0001	-1.29378
<b>Risperidone</b>	43.3929	43.2029	-0.19	(-0.4038,0.0238)	0.0815	-0.43788
<b>Olanzapine</b>	43.9878	43.5756	-0.4122	(-0.9605,0.1361)	0.1405	-0.93709
<b>Mirtazapine</b>	44.5887	43.9802	-0.6085	(-0.7427,-0.4743)	<.0001	-1.36467
<b>Prazosin</b>	43.8804	43.9758	0.09545	(0.0106,0.1803)	0.0274	0.21753
<b>Tricyclics</b>	43.2273	43.1486	-0.07863	(-0.2581,0.1008)	0.3905	-0.1819
<b>Amitriptyline</b>	43.2048	43.1001	-0.1047	(-0.289,0.0795)	0.2651	-0.24242
<b>Imipramine</b>	43.6811	44.1149	0.4337	(-0.3594,1.2268)	0.2828	0.99296

### Propensity Score Weighted Changes in HDL Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	43.8905	43.4947	-0.3958	(-0.5134,-0.2781)	<.0001	-0.90171
<b>Quetiapine</b>	44.069	43.5619	-0.5071	(-0.6537,-0.3605)	<.0001	-1.15066
<b>Risperidone</b>	43.4296	43.2938	-0.1358	(-0.3456,0.074)	0.2045	-0.31264
<b>Olanzapine</b>	44.0951	43.7063	-0.3888	(-0.9342,0.1566)	0.1622	-0.88175
<b>Mirtazapine</b>	44.4911	43.8828	-0.6083	(-0.7414,-0.4752)	<.0001	-1.36726
<b>Prazosin</b>	43.8971	44.0097	0.1127	(0.0273,0.1981)	0.0097	0.2567
<b>Tricyclics</b>	42.9445	42.8614	-0.08312	(-0.2645,0.0983)	0.3691	-0.19355
<b>Amitriptyline</b>	42.9017	42.7962	-0.1055	(-0.2914,0.0804)	0.2661	-0.24587
<b>Imipramine</b>	43.7608	44.0798	0.319	(-0.5101,1.1481)	0.4497	0.72895

### Number of Windows for HDL Cholesterol

Medication Group	n(pre)	n(post)
<b>Antipsychotics</b>	25035	25094
<b>Quetiapine</b>	16780	16786
<b>Risperidone</b>	6945	7034
<b>Olanzapine</b>	1310	1274
<b>Mirtazapine</b>	20128	19179
<b>Prazosin</b>	40692	38688
<b>Tricyclics</b>	8705	8365
<b>Amitriptyline</b>	8309	7956
<b>Imipramine</b>	396	409

### Unweighted Changes in LDL Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	109.08	106.87	-2.2067	(-2.5803,-1.833)	<.0001	-2.02307
<b>Quetiapine</b>	109.6	107.28	-2.3192	(-2.7766,-1.8619)	<.0001	-2.11602
<b>Risperidone</b>	108.17	105.94	-2.2285	(-2.9285,-1.5285)	<.0001	-2.06015
<b>Olanzapine</b>	107.12	106.51	-0.613	(-2.3233,1.0972)	0.482	-0.57228
<b>Mirtazapine</b>	106.05	104.67	-1.385	(-1.8008,-0.9691)	<.0001	-1.30593
<b>Prazosin</b>	109.56	106.55	-3.0158	(-3.305,-2.7267)	<.0001	-2.75256
<b>Tricyclics</b>	108.45	105.79	-2.6638	(-3.2943,-2.0333)	<.0001	-2.45625
<b>Amitriptyline</b>	108.57	105.79	-2.7733	(-3.4212,-2.1254)	<.0001	-2.55445
<b>Imipramine</b>	105.98	105.53	-0.4501	(-3.1789,2.2787)	0.7458	-0.42473

### Propensity Score Weighted Changes in LDL Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	108.88	106.79	-2.0862	(-2.4572,-1.7151)	<.0001	-1.91601
<b>Quetiapine</b>	109.46	107.27	-2.1953	(-2.6493,-1.7413)	<.0001	-2.00552
<b>Risperidone</b>	107.86	105.83	-2.0315	(-2.7269,-1.3361)	<.0001	-1.88351
<b>Olanzapine</b>	106.87	105.95	-0.9227	(-2.6246,0.7791)	0.2876	-0.86342
<b>Mirtazapine</b>	107.55	106.27	-1.283	(-1.6973,-0.8687)	<.0001	-1.19291
<b>Prazosin</b>	108.81	105.68	-3.1239	(-3.4142,-2.8336)	<.0001	-2.87102
<b>Tricyclics</b>	109.41	106.7	-2.711	(-3.3383,-2.0837)	<.0001	-2.47777
<b>Amitriptyline</b>	109.56	106.78	-2.7882	(-3.4335,-2.143)	<.0001	-2.54484
<b>Imipramine</b>	106.52	105.28	-1.2384	(-3.9154,1.4386)	0.3635	-1.16261

### Number of Windows for LDL Cholesterol

Medication Group	n(pre)	n(post)
<b>Antipsychotics</b>	24774	24866
<b>Quetiapine</b>	16582	16643
<b>Risperidone</b>	6892	6953
<b>Olanzapine</b>	1300	1270
<b>Mirtazapine</b>	19957	19087
<b>Prazosin</b>	40525	38597
<b>Tricyclics</b>	8621	8294
<b>Amitriptyline</b>	8230	7888
<b>Imipramine</b>	391	406

### Unweighted Changes in Total Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	183.96	182.41	-1.5527	(-1.9908,-1.1146)	<.0001	-0.84403
<b>Quetiapine</b>	184.57	183.12	-1.4421	(-1.9776,-0.9067)	<.0001	-0.78136
<b>Risperidone</b>	182.86	180.67	-2.1895	(-3.0118,-1.3672)	<.0001	-1.19737
<b>Olanzapine</b>	181.99	182.46	0.4728	(-1.5421,2.4877)	0.6453	0.25979
<b>Mirtazapine</b>	180.44	180.47	0.03437	(-0.4638,0.5326)	0.8924	0.01905
<b>Prazosin</b>	184.44	181.32	-3.1251	(-3.4647,-2.7856)	<.0001	-1.69437
<b>Tricyclics</b>	184.06	181.79	-2.2717	(-3.0121,-1.5312)	<.0001	-1.23422
<b>Amitriptyline</b>	184.26	181.94	-2.3159	(-3.0762,-1.5557)	<.0001	-1.25688
<b>Imipramine</b>	179.86	178.58	-1.2827	(-4.5484,1.9829)	0.4403	-0.71318

### Propensity Score Weighted Changes in Total Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	183.81	182.35	-1.4588	(-1.8939,-1.0237)	<.0001	-0.79366
<b>Quetiapine</b>	184.47	183.12	-1.3429	(-1.8739,-0.812)	<.0001	-0.728
<b>Risperidone</b>	182.57	180.55	-2.0156	(-2.8347,-1.1966)	<.0001	-1.10406
<b>Olanzapine</b>	181.87	182.04	0.1719	(-1.8381,2.1819)	0.8667	0.09454
<b>Mirtazapine</b>	182.09	182.26	0.1674	(-0.3288,0.6637)	0.5084	0.09196
<b>Prazosin</b>	183.82	180.57	-3.2483	(-3.59,-2.9067)	<.0001	-1.76715
<b>Tricyclics</b>	184.45	182.22	-2.2301	(-2.9641,-1.496)	<.0001	-1.20901
<b>Amitriptyline</b>	184.69	182.48	-2.2098	(-2.9631,-1.4566)	<.0001	-1.19654
<b>Imipramine</b>	180	177.56	-2.4431	(-5.7306,0.8444)	0.1447	-1.35728

### Number of Windows for Total Cholesterol

Medication Group	n(pre)	n(post)
<b>Antipsychotics</b>	24707	24836
<b>Quetiapine</b>	16615	16672
<b>Risperidone</b>	6793	6896
<b>Olanzapine</b>	1299	1268
<b>Mirtazapine</b>	19897	19027
<b>Prazosin</b>	40324	38285
<b>Tricyclics</b>	8591	8286
<b>Amitriptyline</b>	8201	7883
<b>Imipramine</b>	390	403



### Unweighted Changes in Systolic Blood Pressure

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	129.55	128.82	-0.7341	(-0.856,-0.6123)	<.0001	-0.56668
<b>Quetiapine</b>	129.5	128.92	-0.5774	(-0.7256,-0.4292)	<.0001	-0.44587
<b>Risperidone</b>	129.76	128.52	-1.2315	(-1.4632,-0.9997)	<.0001	-0.94906
<b>Olanzapine</b>	129.12	129	-0.1276	(-0.6794,0.4242)	0.6501	-0.09884
<b>Mirtazapine</b>	129.27	129.58	0.3096	(0.1744,0.4449)	<.0001	0.23951
<b>Prazosin</b>	130.72	129.87	-0.8539	(-0.9468,-0.7611)	<.0001	-0.65326
<b>Tricyclics</b>	129.09	129.02	-0.06528	(-0.2526,0.1221)	0.4946	-0.05057
<b>Amitriptyline</b>	129.08	128.96	-0.12	(-0.3118,0.0717)	0.2197	-0.09299
<b>Imipramine</b>	129.21	130.27	1.0521	(0.174,1.9301)	0.019	0.81421

### Propensity Score Weighted Changes in Systolic Blood Pressure

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	129.36	128.72	-0.6439	(-0.7643,-0.5236)	<.0001	-0.49778
<b>Quetiapine</b>	129.3	128.81	-0.4861	(-0.6328,-0.3394)	<.0001	-0.37597
<b>Risperidone</b>	129.59	128.49	-1.098	(-1.3258,-0.8703)	<.0001	-0.84733
<b>Olanzapine</b>	128.96	128.73	-0.2384	(-0.7858,0.309)	0.3931	-0.18484
<b>Mirtazapine</b>	128.97	129.33	0.3557	(0.2227,0.4887)	<.0001	0.27579
<b>Prazosin</b>	130.97	130.06	-0.9067	(-1.0003,-0.8131)	<.0001	-0.69231
<b>Tricyclics</b>	129.35	129.29	-0.0556	(-0.2446,0.1334)	0.5642	-0.04298
<b>Amitriptyline</b>	129.34	129.22	-0.1236	(-0.3173,0.0701)	0.2111	-0.09554
<b>Imipramine</b>	129.51	130.74	1.2259	(0.3691,2.0828)	0.0051	0.94657

### Number of Windows for Systolic Blood Pressure

Medication Group	n(pre)	n(post)
<b>Antipsychotics</b>	30821	30509
<b>Quetiapine</b>	20741	20518
<b>Risperidone</b>	8477	8418
<b>Olanzapine</b>	1603	1573
<b>Mirtazapine</b>	24203	23914
<b>Prazosin</b>	50323	49371
<b>Tricyclics</b>	10481	10362
<b>Amitriptyline</b>	9996	9877
<b>Imipramine</b>	485	485

### Unweighted Changes in Diastolic Blood Pressure

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	77.8874	77.6304	-0.257	(-0.338,-0.176)	<.0001	-0.32998
<b>Quetiapine</b>	78.0719	77.9444	-0.1275	(-0.2262,-0.0288)	0.0114	-0.16331
<b>Risperidone</b>	77.572	76.9396	-0.6324	(-0.7867,-0.478)	<.0001	-0.81518
<b>Olanzapine</b>	77.1724	77.2305	0.05811	(-0.2939,0.4101)	0.7461	0.0753
<b>Mirtazapine</b>	77.3705	77.4969	0.1263	(0.0379,0.2148)	0.0051	0.16328
<b>Prazosin</b>	78.9427	78.2588	-0.6839	(-0.7468,-0.6209)	<.0001	-0.8663
<b>Tricyclics</b>	77.4531	77.7559	0.3028	(0.1763,0.4294)	<.0001	0.39096
<b>Amitriptyline</b>	77.4771	77.7511	0.274	(0.1444,0.4036)	<.0001	0.35366
<b>Imipramine</b>	76.9566	77.8461	0.8894	(0.3055,1.4734)	0.0029	1.15576

### Propensity Score Weighted Changes in Diastolic Blood Pressure

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95% CI	P-value	Percent Change (post minus pre)
<b>Antipsychotics</b>	77.8044	77.5632	-0.2413	(-0.3215,-0.1611)	<.0001	-0.3288
<b>Quetiapine</b>	77.9664	77.8593	-0.1071	(-0.205,-0.0093)	0.0318	-0.15677
<b>Risperidone</b>	77.5189	76.9283	-0.5906	(-0.7431,-0.438)	<.0001	-0.78161
<b>Olanzapine</b>	77.224	77.1279	-0.09601	(-0.4443,0.2523)	0.5888	-0.13332
<b>Mirtazapine</b>	77.7019	77.8867	0.1848	(0.096,0.2736)	<.0001	0.2392
<b>Prazosin</b>	78.8149	78.1014	-0.7135	(-0.7762,-0.6509)	<.0001	-0.91271
<b>Tricyclics</b>	77.7431	78.0908	0.3477	(0.2174,0.4779)	<.0001	0.43758
<b>Amitriptyline</b>	77.7911	78.1002	0.3091	(0.1759,0.4423)	<.0001	0.38961
<b>Imipramine</b>	76.8296	77.9029	1.0733	(0.453,1.6936)	0.0007	1.34577

### Number of Windows for Diastolic Blood Pressure

Medication Group	n(pre)	n(post)
<b>Antipsychotics</b>	30821	30509
<b>Quetiapine</b>	20741	20518
<b>Risperidone</b>	8477	8418
<b>Olanzapine</b>	1603	1573
<b>Mirtazapine</b>	24203	23914
<b>Prazosin</b>	50323	49371
<b>Tricyclics</b>	10481	10362
<b>Amitriptyline</b>	9996	9877
<b>Imipramine</b>	485	485

**Tables - Post-Index Outcomes**

**Unweighted New Diagnoses of Cardiovascular Risk Factors (per 100 person years) by Augmenting Medication Group**

Medication Group	Antipsychotics	Mirtazapine	Prazosin	Tricyclics
	Count per 100 person years	Count per 100 person years	Count per 100 person years	Count per 100 person years
Diabetes	4.6806	4.1603	3.3868	4.563
Dyslipidemia	19.8758	16.7212	13.6895	17.4683
Hypertension	15.0191	13.437	9.6776	13.2184
Obesity	9.2964	8.3024	8.9912	9.5792

**Propensity Score Weighted New Diagnoses of Cardiovascular Risk Factors (per 100 person years) by Augmenting Medication Group**

Medication Group	Antipsychotics	Mirtazapine	Prazosin	Tricyclics
	Count per 100 person years	Count per 100 person years	Count per 100 person years	Count per 100 person years
Diabetes	4.3195	3.9309	3.6884	4.4264
Dyslipidemia	18.6484	16.2168	14.7088	17.162
Hypertension	13.4506	12.5179	10.7959	12.577
Obesity	9.1849	8.5802	9.0664	8.802

**New Prescription or Dose Increase of a Diabetes Medication by Augmenting Medication Group**

Medication Group	prescribed new medication	with dose/potency increase	with new medication or dose/potency increase
	% (N)	% (N)	% (N)
Prazosin N=52289	7.619(3984)	3.639(1903)	9.346(4887)
Antipsychotics N=31929	8.275(2642)	4.034(1288)	10.135(3236)
Mirtazapine N=24907	8.728(2174)	4.497(1120)	10.704(2666)
Tricyclics N=10637	10.999(1170)	5.772(614)	13.491(1435)

**New Prescription or Dose Increase of a Cholesterol Medication by Augmenting Medication Group**

Medication Group	prescribed new medication	with dose/potency increase	with new medication or dose/potency increase
	% (N)	% (N)	% (N)
Prazosin N=52289	14.783(7730)	7.944(4154)	20.119(10520)
Antipsychotics N=31929	17.971(5738)	9.8(3129)	23.941(7644)
Mirtazapine N=24907	16.726(4166)	9.564(2382)	22.813(5682)
Tricyclics N=10637	18.172(1933)	10.604(1128)	24.904(2649)

**New Prescription or Dose/Potency Increase of a Statin by Augmenting Medication Group**

Medication Group	prescribed new medication	with dose/potency increase	with new medication or dose/potency increase
	% (N)	% (N)	% (N)
Prazosin N=52289	11.985(6267)	7.221(3776)	17.294(9043)
Antipsychotics N=31929	14.003(4471)	8.857(2828)	20.145(6432)
Mirtazapine N=24907	12.884(3209)	8.576(2136)	19.083(4753)
Tricyclics N=10637	13.603(1447)	9.373(997)	20.551(2186)

**New Prescription or Dose Increase of a Blood Pressure Medication by Augmenting Medication Group**

Medication Group	prescribed new medication	with dose/potency increase	with new medication or dose/potency increase
	% (N)	% (N)	% (N)
Prazosin N=52289	10.461(5470)	21.429(11205)	29.046(15188)
Antipsychotics N=31929	11.143(3558)	24.429(7800)	32.272(10304)
Mirtazapine N=24907	10.732(2673)	25.174(6270)	32.722(8150)
Tricyclics N=10637	11.178(1189)	27.075(2880)	34.784(3700)

**Models - Change in Outcomes**

For all subsequent model tables:

**Model 0: Unadjusted**

**Model 1: Adding sociodemographics, comorbidities, prescribing facility factors, service utilization factors**

**Model 2: Model 1 covariates + days on index medication**

**Model 3: Model 1 covariates + days on index medication + dose of index medication**

**Model 4: Propensity weighted**

**Model 5: Propensity weighted + days on index medication**

**Model 6: Propensity weighted + days on index medication + dose of index medication**

**Unadjusted and Adjusted Models for Change in Weight by Augmenting Medication Group**

Weight	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.6472	(0.5, 0.7945)	<.0001	0.6476	(0.5003, 0.7948)	<.0001	0.6476	(0.5003, 0.7948)	<.0001
Mirtazapine	1.5088	(1.3498, 1.6678)	<.0001	1.5091	(1.3501, 1.668)	<.0001	1.5092	(1.3503, 1.6682)	<.0001
Tricyclics	0.6031	(0.3868, 0.8194)	<.0001	0.6026	(0.3864, 0.8189)	<.0001	0.603	(0.3868, 0.8193)	<.0001
Weight	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.6476	(0.5004, 0.7948)	<.0001	0.7543	(0.5851, 0.9236)	<.0001	0.7544	(0.5852, 0.9236)	<.0001
Mirtazapine	1.5092	(1.3503, 1.6682)	<.0001	1.8473	(1.678, 2.0167)	<.0001	1.8475	(1.6781, 2.0168)	<.0001
Tricyclics	0.6031	(0.3868, 0.8193)	<.0001	0.7163	(0.5469, 0.8858)	<.0001	0.7167	(0.5473, 0.8862)	<.0001
Weight	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	0.7544	(0.5852, 0.9237)	<.0001						
Mirtazapine	1.8475	(1.6781, 2.0168)	<.0001						
Tricyclics	0.7167	(0.5473, 0.8862)	<.0001						

**Unadjusted and Adjusted Models for Change in A1C by Augmenting Medication Group**

A1C	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.01754	(-0.0016, 0.0366)	0.0719	0.02766	(0.0088, 0.0465)	0.0041	0.02768	(0.0088, 0.0466)	0.0041
Mirtazapine	0.1313	(0.1108, 0.1518)	<.0001	0.1323	(0.1119, 0.1526)	<.0001	0.1323	(0.1119, 0.1526)	<.0001
Tricyclics	0.06839	(0.0412, 0.0955)	<.0001	0.07015	(0.0433, 0.097)	<.0001	0.07012	(0.0432, 0.097)	<.0001
A1C	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.0277	(0.0088, 0.0466)	0.0041	0.02408	(0.0023, 0.0458)	0.0299	0.02402	(0.0023, 0.0458)	0.0303
Mirtazapine	0.1322	(0.1119, 0.1525)	<.0001	0.1378	(0.1157, 0.1598)	<.0001	0.1377	(0.1157, 0.1598)	<.0001
Tricyclics	0.07011	(0.0432, 0.097)	<.0001	0.08907	(0.0673, 0.1108)	<.0001	0.08915	(0.0674, 0.1109)	<.0001
A1C	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	0.02401	(0.0023, 0.0457)	0.0304						
Mirtazapine	0.1378	(0.1157, 0.1598)	<.0001						
Tricyclics	0.08917	(0.0674, 0.1109)	<.0001						

**Unadjusted and Adjusted Models for Change in Glucose by Augmenting Medication Group**

Glucose	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.1634	(-0.7515, 0.4247)	0.586	-0.01717	(-0.6019, 0.5676)	0.9541	-0.01709	(-0.6019, 0.5677)	0.9543
Mirtazapine	1.9535	(1.3203, 2.5866)	<.0001	1.9477	(1.318, 2.5775)	<.0001	1.9474	(1.3176, 2.5771)	<.0001
Tricyclics	0.8546	(-0.006, 1.7152)	0.0516	0.8553	(-0.0009, 1.7116)	0.0502	0.8548	(-0.0015, 1.711)	0.0504
Glucose	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.0157	(-0.6005, 0.5691)	0.958	0.01931	(-0.6583, 0.6969)	0.9555	0.02033	(-0.6572, 0.6979)	0.9531
Mirtazapine	1.9456	(1.3159, 2.5754)	<.0001	2.0346	(1.3551, 2.7142)	<.0001	2.039	(1.3595, 2.7185)	<.0001
Tricyclics	0.8548	(-0.0014, 1.711)	0.0504	0.8103	(0.1284, 1.4921)	0.0198	0.8185	(0.1367, 1.5002)	0.0186
Glucose	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	0.02028	(-0.6573, 0.6978)	0.9532						
Mirtazapine	2.039	(1.3596, 2.7185)	<.0001						
Tricyclics	0.8185	(0.1367, 1.5002)	0.0186						

**Unadjusted and Adjusted Models for Change in Triglycerides by Augmenting Medication Group**

Triglycerides	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	7.6698	(5.7836, 9.556)	<.0001	7.6897	(5.8063, 9.5731)	<.0001	7.6894	(5.806, 9.5727)	<.0001
Mirtazapine	14.0019	(11.9669, 16.0368)	<.0001	13.8757	(11.8438, 15.9077)	<.0001	13.8805	(11.8486, 15.9124)	<.0001
Tricyclics	4.474	(1.6944, 7.2535)	0.0016	4.4662	(1.6905, 7.2419)	0.0016	4.4709	(1.6953, 7.2465)	0.0016
Triglycerides	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	7.6945	(5.8112, 9.5778)	<.0001	7.9791	(5.8281, 10.1301)	<.0001	7.9872	(5.8363, 10.138)	<.0001
Mirtazapine	13.8715	(11.8397, 15.9033)	<.0001	14.8648	(12.7023, 17.0273)	<.0001	14.8678	(12.7055, 17.0301)	<.0001
Tricyclics	4.4704	(1.6948, 7.2459)	0.0016	5.3652	(3.1948, 7.5356)	<.0001	5.3691	(3.1989, 7.5393)	<.0001
Triglycerides	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	7.9914	(5.8406, 10.1422)	<.0001						
Mirtazapine	14.8593	(12.697, 17.0216)	<.0001						
Tricyclics	5.3679	(3.1977, 7.5381)	<.0001						

**Unadjusted and Adjusted Models for Change in HDL Cholesterol by Augmenting Medication Group**

HDL	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.5477	(-0.6917, -0.4036)	<.0001	-0.5529	(-0.6966, -0.4092)	<.0001	-0.5529	(-0.6966, -0.4092)	<.0001
Mirtazapine	-0.699	(-0.8543, -0.5438)	<.0001	-0.6901	(-0.845, -0.5352)	<.0001	-0.6904	(-0.8453, -0.5355)	<.0001
Tricyclics	-0.1711	(-0.3825, 0.0403)	0.1127	-0.1641	(-0.3751, 0.0469)	0.1274	-0.1642	(-0.3752, 0.0468)	0.1273
HDL	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.5531	(-0.6968, -0.4094)	<.0001	-0.505	(-0.6701, -0.3399)	<.0001	-0.5054	(-0.6705, -0.3403)	<.0001
Mirtazapine	-0.6901	(-0.845, -0.5352)	<.0001	-0.717	(-0.8831, -0.5509)	<.0001	-0.7173	(-0.8834, -0.5512)	<.0001
Tricyclics	-0.1642	(-0.3752, 0.0469)	0.1273	-0.1919	(-0.3583, -0.0254)	0.0239	-0.1916	(-0.358, -0.0251)	0.0241
HDL	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	-0.5056	(-0.6707, -0.3405)	<.0001						
Mirtazapine	-0.717	(-0.8831, -0.5509)	<.0001						
Tricyclics	-0.1915	(-0.358, -0.0251)	0.0241						

**Unadjusted and Adjusted Models for Change in LDL Cholesterol by Augmenting Medication Group**

LDL	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.7933	(0.3226, 1.264)	0.001	0.6311	(0.1614, 1.1008)	0.0085	0.6311	(0.1614, 1.1008)	0.0085
Mirtazapine	1.6295	(1.1225, 2.1365)	<.0001	1.5791	(1.073, 2.0851)	<.0001	1.5755	(1.0694, 2.0815)	<.0001
Tricyclics	0.3464	(-0.3458, 1.0386)	0.3266	0.3412	(-0.3498, 1.0322)	0.3331	0.3398	(-0.3512, 1.0308)	0.3352
LDL	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.6315	(0.1618, 1.1012)	0.0084	1.0298	(0.4912, 1.5684)	0.0002	1.0262	(0.4877, 1.5648)	0.0002
Mirtazapine	1.5749	(1.0689, 2.081)	<.0001	1.8503	(1.3091, 2.3916)	<.0001	1.8461	(1.3049, 2.3873)	<.0001
Tricyclics	0.3398	(-0.3512, 1.0308)	0.3352	0.4128	(-0.13, 0.9557)	0.1361	0.4128	(-0.13, 0.9556)	0.1361
LDL	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	1.0274	(0.4888, 1.5659)	0.0002						
Mirtazapine	1.8446	(1.3034, 2.3857)	<.0001						
Tricyclics	0.4124	(-0.1304, 0.9552)	0.1364						

**Unadjusted and Adjusted Models for Change in Total Cholesterol by Augmenting Medication Group**

Total Cholesterol	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.5538	(0.9992, 2.1084)	<.0001	1.3858	(0.8321, 1.9396)	<.0001	1.3855	(0.8318, 1.9393)	<.0001
Mirtazapine	3.1491	(2.5514, 3.7468)	<.0001	3.0819	(2.4851, 3.6787)	<.0001	3.0802	(2.4834, 3.6771)	<.0001
Tricyclics	0.852	(0.0365, 1.6675)	0.0406	0.8371	(0.0227, 1.6515)	0.0439	0.8359	(0.0214, 1.6503)	0.0443
Total Cholesterol	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.3862	(0.8324, 1.9399)	<.0001	1.7785	(1.1423, 2.4147)	<.0001	1.7747	(1.1385, 2.4108)	<.0001
Mirtazapine	3.0784	(2.4816, 3.6752)	<.0001	3.4152	(2.7759, 4.0545)	<.0001	3.4146	(2.7754, 4.0539)	<.0001
Tricyclics	0.8359	(0.0214, 1.6503)	0.0443	1.0256	(0.3844, 1.6667)	0.0017	1.0244	(0.3833, 1.6655)	0.0017
Total Cholesterol	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	1.7757	(1.1396, 2.4119)	<.0001						
Mirtazapine	3.411	(2.7718, 4.0502)	<.0001						
Tricyclics	1.0243	(0.3832, 1.6654)	0.0017						



**Unadjusted and Adjusted Models for Change in Systolic Blood Pressure by Augmenting Medication Group**

Systolic	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.1199	(-0.0312, 0.2709)	0.12	0.1296	(-0.0214, 0.2806)	0.0926	0.1297	(-0.0213, 0.2807)	0.0923
Mirtazapine	1.1641	(1.0008, 1.3273)	<.0001	1.1695	(1.0063, 1.3327)	<.0001	1.1693	(1.0061, 1.3325)	<.0001
Tricyclics	0.7899	(0.5665, 1.0133)	<.0001	0.7976	(0.5743, 1.021)	<.0001	0.7969	(0.5736, 1.0203)	<.0001
Systolic	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.1298	(-0.0213, 0.2808)	0.0922	0.2629	(0.092, 0.4339)	0.0026	0.2629	(0.092, 0.4339)	0.0026
Mirtazapine	1.1691	(1.0059, 1.3322)	<.0001	1.2631	(1.0921, 1.4341)	<.0001	1.2631	(1.0921, 1.4341)	<.0001
Tricyclics	0.7971	(0.5737, 1.0204)	<.0001	0.8526	(0.6811, 1.0241)	<.0001	0.8527	(0.6812, 1.0242)	<.0001
Systolic	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	0.263	(0.092, 0.434)	0.0026						
Mirtazapine	1.263	(1.092, 1.434)	<.0001						
Tricyclics	0.8528	(0.6813, 1.0243)	<.0001						

**Unadjusted and Adjusted Models for Change in Diastolic Blood Pressure by Augmenting Medication Group**

Diastolic	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.4268	(0.3257, 0.5278)	<.0001	0.4188	(0.3177, 0.5198)	<.0001	0.4188	(0.3178, 0.5199)	<.0001
Mirtazapine	0.8103	(0.7011, 0.9194)	<.0001	0.8067	(0.6975, 0.9159)	<.0001	0.8066	(0.6974, 0.9158)	<.0001
Tricyclics	0.987	(0.8376, 1.1364)	<.0001	0.9777	(0.8283, 1.1271)	<.0001	0.9774	(0.828, 1.1269)	<.0001
Diastolic	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.4189	(0.3178, 0.5199)	<.0001	0.4721	(0.3571, 0.5871)	<.0001	0.4721	(0.3571, 0.5871)	<.0001
Mirtazapine	0.8064	(0.6972, 0.9156)	<.0001	0.8983	(0.7834, 1.0133)	<.0001	0.8983	(0.7833, 1.0133)	<.0001
Tricyclics	0.9776	(0.8282, 1.127)	<.0001	1.0613	(0.946, 1.1767)	<.0001	1.0608	(0.9454, 1.1761)	<.0001
Diastolic	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	0.4722	(0.3572, 0.5872)	<.0001						
Mirtazapine	0.898	(0.783, 1.013)	<.0001						
Tricyclics	1.0611	(0.9458, 1.1764)	<.0001						

**Models - Post-Index Outcomes**

For all subsequent model tables:

**Model 0: Unadjusted**

**Model 1: Adding sociodemographics, comorbidities, prescribing facility factors, service utilization factors**

**Model 2: Model 1 covariates + days on index medication**

**Model 3: Model 1 covariates + days on index medication + dose of index medication**

**Model 4: Propensity weighted**

**Model 5: Propensity weighted + days on index medication**

**Model 6: Propensity weighted + days on index medication + dose of index medication**

**Difference in Incident Diagnoses of Diabetes per 100 Person Years (Reference Group Prazosin)**

Dx Diabetes	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.29381	(0.9846, 1.603)	<.0001	0.85796	(0.6133, 1.1026)	<.0001	0.80716	(0.5623, 1.052)	<.0001
Mirtazapine	0.77352	(0.4457, 1.1014)	<.0001	0.2815	(0.028, 0.535)	0.0295	0.31741	(0.0608, 0.5741)	0.0154
Tricyclics	1.17618	(0.7098, 1.6426)	<.0001	1.04497	(0.6605, 1.4295)	<.0001	1.10825	(0.7183, 1.4982)	<.0001
Dx Diabetes	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.86516	(0.6122, 1.1181)	<.0001	0.63109	(0.2683, 0.9939)	0.0007	0.4973	(0.1436, 0.851)	0.0059
Mirtazapine	-0.09162	(-0.3942, 0.211)	0.5529	0.24253	(-0.1104, 0.5954)	0.178	0.33027	(-0.0222, 0.6828)	0.0663
Tricyclics	1.16558	(0.7637, 1.5675)	<.0001	0.73806	(0.3675, 1.1086)	<.0001	0.84496	(0.474, 1.2159)	<.0001
Dx Diabetes	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	0.54923	(0.1856, 0.9129)	0.0031						
Mirtazapine	-0.18452	(-0.5906, 0.2216)	0.3731						
Tricyclics	0.89837	(0.5175, 1.2793)	<.0001						

**Difference in Incident Diagnoses of Dyslipidemia per 100 Person Years (Reference Group Prazosin)**

Dx Dyslipidemia	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	6.18623	(5.4133, 6.9591)	<.0001	4.05	(3.0433, 5.0567)	<.0001	3.90801	(2.8393, 4.9768)	<.0001
Mirtazapine	3.03167	(2.1906, 3.8727)	<.0001	1.47571	(0.3968, 2.5546)	0.0073	1.61279	(0.4566, 2.769)	0.0063
Tricyclics	3.77875	(2.6195, 4.938)	<.0001	3.21834	(1.663, 4.7737)	<.0001	3.36527	(1.7007, 5.0298)	<.0001
Dx Dyslipidemia	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	4.04292	(2.9651, 5.1208)	<.0001	3.93961	(3.0269, 4.8524)	<.0001	3.59481	(2.6916, 4.498)	<.0001
Mirtazapine	0.7108	(-0.6693, 2.0909)	0.3128	1.50801	(0.6174, 2.3986)	0.0009	1.85951	(0.964, 2.755)	<.0001
Tricyclics	3.45731	(1.7829, 5.1317)	<.0001	2.45327	(1.5401, 3.3665)	<.0001	2.77784	(1.8606, 3.6951)	<.0001
Dx Dyslipidemia	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	3.69756	(2.7851, 4.61)	<.0001						
Mirtazapine	0.97159	(-0.0884, 2.0316)	0.0724						
Tricyclics	2.84903	(1.9234, 3.7747)	<.0001						

**Difference in Incident Diagnoses of Hypertension per 100 Person Years (Reference Group Prazosin)**

Dx Hypertension	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	5.34155	(4.6675, 6.0156)	<.0001	2.92334	(2.4158, 3.4308)	<.0001	2.78595	(2.2774, 3.2945)	<.0001
Mirtazapine	3.75944	(3.0289, 4.49)	<.0001	1.52167	(0.9818, 2.0615)	<.0001	1.59265	(1.0474, 2.1379)	<.0001
Tricyclics	3.54083	(2.5548, 4.5268)	<.0001	2.56656	(1.7888, 3.3443)	<.0001	2.6576	(1.8723, 3.4429)	<.0001
Dx Hypertension	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.90882	(2.3887, 3.429)	<.0001	2.65465	(1.8582, 3.4511)	<.0001	2.29422	(1.5082, 3.0802)	<.0001
Mirtazapine	0.71156	(0.0549, 1.3682)	0.0337	1.72196	(0.9399, 2.504)	<.0001	1.94227	(1.1565, 2.7281)	<.0001
Tricyclics	2.74492	(1.9439, 3.5459)	<.0001	1.78109	(0.9891, 2.5731)	<.0001	1.97685	(1.1819, 2.7718)	<.0001
Dx Hypertension	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	2.39535	(1.5977, 3.193)	<.0001						
Mirtazapine	0.99714	(0.0685, 1.9258)	0.0353						
Tricyclics	2.0506	(1.2448, 2.8564)	<.0001						

**Difference in Incident Diagnoses of Obesity per 100 Person Years (Reference Group Prazosin)**

Dx Obesity	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.30518	(-0.1682, 0.7786)	0.2064	0.53492	(0.019, 1.0508)	0.0421	0.37929	(-0.1367, 0.8953)	0.1497
Mirtazapine	-0.68876	(-1.1912, -0.1864)	0.0072	-0.56391	(-1.1137, -0.0141)	0.0444	-0.45829	(-1.014, 0.0974)	0.106
Tricyclics	0.58798	(-0.1402, 1.3161)	0.1135	0.35196	(-0.4275, 1.1314)	0.3762	0.46215	(-0.3249, 1.2492)	0.2498
Dx Obesity	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.42948	(-0.0948, 0.9537)	0.1083	0.11845	(-0.4338, 0.6707)	0.6742	-0.00191	(-0.5511, 0.5472)	0.9945
Mirtazapine	-1.04552	(-1.7257, -0.3654)	0.0026	-0.48622	(-1.0265, 0.0541)	0.0778	-0.40594	(-0.948, 0.1361)	0.1422
Tricyclics	0.49896	(-0.2991, 1.2971)	0.2204	-0.26448	(-0.8197, 0.2907)	0.3505	-0.17673	(-0.7339, 0.3805)	0.5342
Dx Obesity	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	0.04077	(-0.5159, 0.5975)	0.8859						
Mirtazapine	-0.9335	(-1.5798, -0.2872)	0.0046						
Tricyclics	-0.14659	(-0.7109, 0.4177)	0.6107						

**Comparison of New Prescription or Dose Increase of a Diabetes Medication (Reference Group Prazosin)**

Rx Diabetes	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.78885	(0.3778, 1.1999)	0.0002	0.145	(-0.1879, 0.4778)	0.3932	0.12805	(-0.2052, 0.4613)	0.4514
Mirtazapine	1.35768	(0.909, 1.8063)	<.0001	-0.27578	(-0.6243, 0.0727)	0.1209	-0.26028	(-0.6098, 0.0892)	0.1444
Tricyclics	4.14451	(3.5141, 4.7749)	<.0001	2.18679	(1.6835, 2.6901)	<.0001	2.2099	(1.7053, 2.7145)	<.0001
Rx Diabetes	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.20189	(-0.1403, 0.5441)	0.2476	0.29189	(-0.1907, 0.7745)	0.2359	0.16153	(-0.3177, 0.6408)	0.5088
Mirtazapine	-1.09397	(-1.5165, -0.6715)	<.0001	-0.01139	(-0.4905, 0.4677)	0.9628	0.11289	(-0.368, 0.5938)	0.6454
Tricyclics	2.31318	(1.7966, 2.8298)	<.0001	1.6027	(1.1035, 2.1019)	<.0001	1.73997	(1.2389, 2.241)	<.0001
Rx Diabetes	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	0.17792	(-0.3039, 0.6597)	0.4692						
Mirtazapine	-0.07776	(-0.6584, 0.5029)	0.7929						
Tricyclics	1.75789	(1.2547, 2.2611)	<.0001						

**Comparison of New Prescription or Dose Increase of a Cholesterol Medication (Reference Group Prazosin)**

Rx Cholesterol	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	3.82166	(3.2485, 4.3948)	<.0001	2.80249	(2.2974, 3.3076)	<.0001	2.78044	(2.2746, 3.2863)	<.0001
Mirtazapine	2.69391	(2.079, 3.3088)	<.0001	0.9112	(0.3792, 1.4432)	0.0008	0.93316	(0.4, 1.4663)	0.0006
Tricyclics	4.78468	(3.9348, 5.6346)	<.0001	3.81377	(3.0567, 4.5708)	<.0001	3.83967	(3.0814, 4.598)	<.0001
Rx Cholesterol	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.93127	(2.4169, 3.4457)	<.0001	2.76773	(2.1018, 3.4337)	<.0001	2.61627	(1.9514, 3.2812)	<.0001
Mirtazapine	-0.41255	(-1.0657, 0.2406)	0.2157	1.04773	(0.3917, 1.7038)	0.0017	1.20031	(0.5422, 1.8584)	0.0004
Tricyclics	3.9637	(3.1946, 4.7328)	<.0001	2.43408	(1.7663, 3.1019)	<.0001	2.59229	(1.9223, 3.2622)	<.0001
Rx Cholesterol	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	2.69571	(2.0261, 3.3654)	<.0001						
Mirtazapine	0.42736	(-0.3644, 1.2191)	0.2901						
Tricyclics	2.65129	(1.9773, 3.3253)	<.0001						

**Comparison of New Prescription or Dose/Potency Increase of a Statin (Reference Group Prazosin)**

Rx Statin	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.85043	(2.3109, 3.39)	<.0001	1.98898	(1.504, 2.4739)	<.0001	1.98664	(1.501, 2.4723)	<.0001
Mirtazapine	1.78872	(1.2104, 2.3671)	<.0001	0.23856	(-0.2714, 0.7485)	0.3592	0.24081	(-0.2698, 0.7514)	0.3553
Tricyclics	3.25664	(2.4573, 4.056)	<.0001	2.58372	(1.8577, 3.3097)	<.0001	2.58641	(1.8599, 3.3129)	<.0001
Rx Statin	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.10422	(1.6107, 2.5978)	<.0001	1.94147	(1.3141, 2.5688)	<.0001	1.83186	(1.2054, 2.4583)	<.0001
Mirtazapine	-0.84326	(-1.4692, -0.2173)	0.0083	0.28496	(-0.3312, 0.9011)	0.3647	0.39398	(-0.224, 1.0119)	0.2115
Tricyclics	2.67827	(1.9417, 3.4149)	<.0001	1.31073	(0.684, 1.9375)	<.0001	1.42338	(0.7948, 2.052)	<.0001
Rx Statin	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	1.89755	(1.2664, 2.5287)	<.0001						
Mirtazapine	-0.25039	(-0.9942, 0.4934)	0.5094						
Tricyclics	1.4695	(0.8369, 2.1021)	<.0001						

**Comparison of New Prescription or Dose Increase of a Blood Pressure Medication (Reference Group Prazosin)**

Rx Blood Pressure	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	3.22534	(2.5855, 3.8651)	<.0001	1.86804	(1.2551, 2.481)	<.0001	1.76268	(1.1487, 2.3767)	<.0001
Mirtazapine	3.67546	(2.9821, 4.3689)	<.0001	0.6238	(-0.0314, 1.279)	0.062	0.72687	(0.0691, 1.3847)	0.0303
Tricyclics	5.73798	(4.7807, 6.6952)	<.0001	3.80403	(2.8808, 4.7273)	<.0001	3.91748	(2.9914, 4.8435)	<.0001
Rx Blood Pressure	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.95175	(1.3288, 2.5747)	<.0001	1.65918	(0.919, 2.3994)	<.0001	1.38372	(0.6443, 2.1232)	0.0002
Mirtazapine	-1.41704	(-2.2275, -0.6066)	0.0006	0.64482	(-0.0916, 1.3812)	0.0861	0.93617	(0.1969, 1.6754)	0.0131
Tricyclics	4.07134	(3.1344, 5.0083)	<.0001	2.74714	(1.9992, 3.4951)	<.0001	3.04961	(2.2988, 3.8005)	<.0001
Rx Blood Pressure	Model 6								
	Diff to Ref	95% CI	p-val						
Antipsychotics	1.48515	(0.7412, 2.2291)	<.0001						
Mirtazapine	-0.20931	(-1.1028, 0.6841)	0.6461						
Tricyclics	3.12925	(2.3748, 3.8837)	<.0001						